High and Low Dose Oral Peanut Immunotherapy - Comparison of Efficacy and Safety

Inclusion Criteria: * medical history of peanut allergy, * IgE-mediated peanut allergy confirmed as positive skin prick tests with peanut allergens (diameter of the wheal greater than 3mm) and/or specific IgE level greater than 0.35 kilo units of Allergen per liter (kUA/l) (UniCAP method), * reaction to less than 100 mg of peanut protein during OOFC, * signed Informed Consent by parent/legal guardian and patient aged \>16 years old, * patient's/caregivers' cooperation with researcher. Exclusion Criteria: * no confirmed peanut allergy, * negative oral food challenge with less than 100mg of peanut protein, * severe asthma, * uncontrolled mild/moderate asthma: forced expiratory volume at one second (FEV1)\<80% (under 5. percentile), FEV1/forced vital capacity (FVC)\<75% (under 5. percentile), hospitalization due to asthma exacerbation within last 12 months, * current oral/sublingual/subcutaneous immunotherapy with other allergen, * eosinophilic gastroenteritis, * a history of severe recurrent anaphylaxis episodes, * chronic diseases requiring continuous treatment, including heart disease, epilepsy, metabolic diseases, diabetes, * medication: * oral, daily steroid therapy longer than 1 month within last 12 months, * at least two courses of oral steroid therapy (at least 7 days) within last 12 months, * oral steroid therapy longer than 7 days within last 3 months, * biological treatment, * the need to constantly take antihistamines, * therapy with β-blockers, angio…